Skip to main content
Frontiers in Veterinary Science logoLink to Frontiers in Veterinary Science
. 2026 Feb 26;13:1801648. doi: 10.3389/fvets.2026.1801648

Correction: A proposed framework for practical multimodal management of osteoarthritis in growing dogs

Denis J Marcellin-Little 1,*, Donald A Hulse 2, Janice L Huntingford 3, Tamara Grubb 4, Matthew W Brunke 5, Arielle Pechette Markley 6, Bethany Frank 7
PMCID: PMC12980795  PMID: 41834886

In the published article, there was a mistake in Table 1 as published.

Table 1.

Minimum approved age for current NSAIDs in dogs.

NSAID Brand name, manufacturer Minimum approved age
Carprofen Rimadyl®, Zoetis 6 weeks
Firocoxib Previcox®, Boehringer Ingelheim 7 weeks
Deracoxib Deramaxx™, Elanco 4 months
Robenacoxib Onsior™, Elanco 4 months
Meloxicam Metacam®, Boehringer Ingelheim 6 months
Grapiprant Galliprant®, Elanco 9 months

NSAIDs, non-steroidal anti-inflammatory drug. References: product inserts—June 2024.

The manufacturer of Onsior™ was erroneously listed as Boehringer Ingelheim. The correct manufacturer of Onsior™ is Elanco.

The corrected Table 1 appears below.

The original version of this article has been updated.

Footnotes

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Veterinary Science are provided here courtesy of Frontiers Media SA

RESOURCES